Current concepts and future directions in radioimmunotherapy

Current Drug Discovery Technologies

Volumn 7, Issue 4, 2010, Pages 253-262

  Lin, Frank I ^a   Iagaru, Andrei ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alpha particle; Bexxar ; Lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

ANTINEOPLASTIC AGENT; ASTATINE 211; BISMUTH 213; CARCINOEMBRYONIC ANTIGEN; IBRITUMOMAB TIUXETAN; IODINE 125; IODINE 131; MEMBRANE ANTIGEN; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

ALGORITHM; ALPHA RADIATION; ARTICLE; B CELL LYMPHOMA; BETA RADIATION; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER LOCALIZATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COLON CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNOCOMPETENCE; MULTICENTER STUDY (TOPIC); MYELOID LEUKEMIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; HUMANS; LYMPHOMA; NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 78650719836     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310793360684     Document Type: Article

References (105)

1. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329(7): 459-65.
2. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. Am J Clin Oncol 1991; 9(4): 548-64.
3. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 1987; 2(1): 49-53.
4. Parker BA, Vassos AB, Halpern SE, et al. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 1990; 50(3 Suppl): 1022s-1028s.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495-7.
6. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. 1975. J Immunol 2005; 174(5): 2453-5.
7. Borghaei H, Smith M, Campbell K. Immunotherapy of cancer. Eur J Pharmacol 2009; 625(1-3): 41-54.
8. Illidge TM, Bayne MC. Antibody therapy of lymphoma. Expert Opin Pharmacother 2001; 2(6): 953-61.
9. Sharkey R, Goldenberg D. Novel radioimmunopharmaceuticals for cancer imaging and therapy. Curr Opin Investig Drugs 2008; 9(12): 1302-16.
10. Goldsmith S. Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010; 40(2): 122-35.
11. Dixon KL. The radiation biology of radioimmunotherapy. Nucl Med Commun 2003; 24(9): 951-7.
12. Sousou T, Friedberg J. Rituximab in indolent lymphomas. Semin Hematol 2010; 47(2): 133-42.
13. Sanford M, McCormack P. Ofatumumab. Drugs 2010; 70(8): 10139.
14. Jenab-Wolcott J, Giantonio B. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biological Ther 2009; 9(4): 507-17.
15. Greenhalgh J, Bagust A, Boland A, et al. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technol Assess 2009; 13(Suppl 3): 49-54.
16. Prenen H, Tejpar S, Van Cutsem E. New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res 2010; 16(11): 2921-6.
17. Hudis C. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357(1): 39-51.
18. Barbet J, Cherel M, Chatal J-F. Alpha particles more promising than toxins? Eur J Nucl Med Mol Imaging 2010; 37(5): 849-50.
19. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010; 31(4): 363-72.
20. Witzig T, Flinn I, Gordon L, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20(15): 3262-9.
21. Witzig T, Gordon L, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmuno-therapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20(10): 2453-63.
22. Gordon L, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymph 2004; 5(2): 98-101.
23. Davis T, Kaminski M, Leonard J, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004; 10(23): 7792-8.
24. Morgan W. Non-targeted and delayed effects of exposure to ionizing radiation: I. Radiation-induced genomic instability and bystander effects in vitro. Radiat Res 2003; 159(5): 567-80.
25. Hamada N, Matsumoto H, Hara T, Kobayashi Y. Intercellular and intracellular signaling pathways mediating ionizing radiation-induced bystander effects. J Radiat Res 2007; 48(2): 87-95.
26. Morgan W. Non-targeted and delayed effects of exposure to ionizing radiation: II. Radiation-induced genomic instability and bystander effects in vivo, clastogenic factors and transgenerational effects. Radiat Res 2003; 159(5): 581-96.
27. Munro A. Bystander effects and their implications for clinical radiotherapy. J Radiol Prot 2009; 29(2A).
28. Prise K, O'Sullivan J. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9(5): 351-60.
29. DeVeaux L, Durtschi L, Case J, Wells D. Bystander effects in unicellular organisms. Mutation research. 2006; 597(1-2): 78-86.
30. Bagdonas S, Dahle J, Kaalhus O, Moan J. Cooperative inactivation of cells in microcolonies treated with UVA radiation. Radiat Res 1999; 152(2): 174-9.
31. Dahle J, Bagdonas S, Kaalhus O, Olsen G, Steen HB, Moan J. The bystander effect in photodynamic inactivation of cells. Biochim Biophys Acta 2000; 1475(3): 273-80.
32. Alexandre J, Hu Y, Lu W, Pelicano H, Huang P. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Res 2007; 67(8): 3512-7.
33. Macklis R, Pohlman B. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys 2006; 66(3): 833-41.
34. Davies AJ. Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. Oncogene 2007; 26(25): 3614-28.
35. Macklis R. Radioimmunotherapy as a therapeutic option for Non-Hodgkin's lymphoma. Semin Radiat Oncol 2007; 17(3): 176-83.
36. Pohlman B, Sweetenham J, Macklis R. Review of clinical radioimmunotherapy. Expert Rev Anticancer Ther 2006; 6(3): 44561.
37. Wahl R. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005; 46(Suppl 1): 128S-40S.
38. Bona C, Bonilla FA. Textbook of Immunology. 2nd ed. Amsterdam, Netherlands: Harwood Academic Publishers; 1996.
39. Vervoordeldonk SF, Heikens J, Goedemans WT, et al. 99mTc-CD19 monoclonal antibody is not useful for imaging of B cell non-Hodgkin's lymphoma. Cancer Immunol Immunother 1996; 42(5): 291-6.
40. Ma D, McDevitt MR, Barendswaard E, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia 2002; 16(1): 60-6.
41. Vallera D, Elson M, Brechbiel M, et al. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm 2004; 19(1): 1123.
42. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995; 55(23 Suppl): 5899S-5907S.
43. Linden O, Hindorf C, Cavallin-Stahl E, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 2005; 11(14): 5215-22.
44. Postema E, Raemaekers J, Oyen W, et al. Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. Clin Cancer Res 2003; 9(10 Pt 2): 3995S-4002S.
45. Zhang M, Yao Z, Garmestani K, et al. Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma. Cancer Biother Radiopharm 2009; 24(3): 303-9.
46. Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc Natl Acad Sci USA 2003; 100(4): 1891-5.
47. 131I-labeled chimeric anti-CD25 antibody showing efficacy in patients with refractory lymphoma. Clin Cancer Res 2009; 15(24): 7701-10.
48. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 10(11): 1696711.
49. Pagel J, Hedin N, Subbiah K, et al. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood 2003; 101(6): 2340-8.
50. 131I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma. Blood 2009; 113(23): 5905-10.
51. Green D, Pagel J, Nemecek E, et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. Blood 2009; 114(6): 1226-35.
52. DeNardo GL, DeNardo SJ, Goldstein DS, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16(10): 3246-56.
53. Zhang N, Khawli L, Hu P, Epstein A. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. Cancer Biother Radiopharm 2007; 22(3): 342-56.
54. Liu C, DeNardo G, Tobin E, DeNardo S. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Cancer Biother Radiopharm 2004; 19(5): 545-61.
55. Horning S, Younes A, Jain V, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005; 23(4): 712-9.
56. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19(19): 3918-28.
57. Fisher R, Kaminski M, Wahl R, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23(30): 7565-73.
58. Bennett J, Kaminski M, Leonard J, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 2005; 105(12): 4576-82.
59. Gregory SL, J; Knox, SJ; Zelenetz, A; Armitage, JO; Kaminski, M. The iodine I-131 tositumomab therapeutic regimen: Summary of safety in 995 patients with relapsed/refractory low grade (LG) and transformed LG non-Hodgkin's lymphoma (NHL). Proc Annu Meet Am Assoc Cancer Res 2004; 22: 6732.
60. Witzig T, White C, Gordon L, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. J Clin Oncol 2003; 21(7): 1263-70.
61. 131I- Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol 2010; 12(2): 198-203.
62. 131I-tositumomab in clinical practice. J Nucl Med 2007; 48(11): 1767-76.
63. Palanca-Wessels C, Press O. Improving the efficacy of radioimmunotherapy for non-Hodgkin lymphomas. Cancer 2010; 116(4 Suppl): 1126-33.
64. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26(32): 515664.
65. Devizzi L, Guidetti A, Tarella C, et al. High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 2008; 26(32): 5175-82.
66. Krishnan A, Nademanee A, Fung H, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008; 26(1): 90-5.
67. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106(8): 2896-902.
68. Winter J, Inwards D, Spies S, et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2009; 27(10):1653-9.
69. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000; 97(4): 1802-7.
70. Goldenberg D, Sharkey R, Paganelli G, Barbet J, Chatal J-F. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006; 24(5): 823-34.
71. Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood 2001; 98(8): 253543.
72. Pelegrin A, Robert B. Bispecific antibodies: what future? Med Sci 2009; 25(12): 1155-8.
73. Pagel J, Orgun N, Hamlin D, et al. A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009; 113(20): 4903-13.
74. Pantelias A, Pagel J, Hedin N, et al. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 2007; 109(11): 4980-7.
75. DeNardo G, Tobin E, Chan K, Bradt B, DeNardo S. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res 2005; 11(19 Pt 2): 7075S-7079S.
76. DeNardo S, Denardo G. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys 2006; 66(2 Suppl): S89-95.
77. Chatal J-F, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006; 24(11): 1705-11.
78. Goldenberg DM, DeLand FH, Bennett SJ, et al. Radioimmunodetection of prostatic cancer. In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging. JAMA 1983; 250(5): 630-5.
79. Meredith RF, Bueschen AJ, Khazaeli MB, et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994; 35(6): 1017-22.
80. Tagawa S, Beltran H, Vallabhajosula S, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 2010; 16(4 Suppl): 1075-83.
81. 131I-labeled anti-CEA monoclonal antibody. Bioconjug Chem 2010; 21(2): 314-8.
82. de Jong G, Hendriks T, Eek A, et al. Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin. Ann Surg Oncol 2009; 16(7): 2065-73.
83. Knox SJ, Goris ML, Tempero M, et al. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000; 6(2): 406-14.
84. 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm 2006; 21(3): 243-56.
85. DeNardo S. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 2005; 35(2): 143-51.
86. DeNardo SJ, O'Grady LF, Richman CM, DeNardo GL. Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. Adv Exp Med Biol 1994; 353: 203-11.
87. Denardo SJ, O'Grady LF, Richman CM, et al. Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody. Anticancer Res 1997; 17(3B): 1745-51.
88. Song H, Hobbs R, Vajravelu R, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res 2009; 69(23): 8941-8.
89. DeNardo SJ, Kramer EL, O'Donnell RT, et al. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med 1997; 38(8): 1180-5.
90. Wong JY, Somlo G, Odom-Maryon T, et al. Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res 1999; 5(10 Suppl): 3224S-3231S.
91. Karacay H, Sharkey R, Gold D, et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009; 50(12): 2008-16.
92. Modak S, Cheung N-K. Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat Rev 2010; 36(4): 307-17.
93. Bouchelouche K, Capala J. 'Image and treat': an individualized approach to urological tumors. Current Opin Oncol 2010; 22(3): 274-80.
94. Dadachova E, Casadevall A. Radioimmunotherapy of infectious diseases. Semin Nucl Med 2009; 39(2): 146-53.
95. Dadachova E. Radioimmunotherapy of infection with Bi-labeled antibodies. Curr Radiopharm 2008; 1(3): 234-9.
96. Bryan R, Jiang Z, Howell R, et al. Radioimmunotherapy Is More Effective than Antifungal Treatment in Experimental Cryptococcal Infection. J Infect Dis 2010; 202(4): 633-7.
97. Otte A. Does health economics have an impact on non-Hodgkin's lymphoma patients' options? Nucl Med Commun 2008; 29(8): 7489.
98. Berenson A. Market Forces Cited in Lymphoma Drug's Disuse. New York Times. 7/14/2007. Available from http://www.nytimes. com/2007/07/14/health/ 14lymphoma.html (Accessed 8/27/2010).
99. Schaefer N, Ma J, Huang P, Buchanan J, Wahl R. Radioimmunotherapy in non-Hodgkin lymphoma: opinions of U.S. medical oncologists and hematologists. J Nucl Med 2010; 51(6): 987-94.
100. Brechbiel M. Targeted alpha-therapy: past, present, future? Dalton Trans (Cambridge, England 2003). 2007; (43): 4918-28.
101. Karagiannis T. Comparison of different classes of radionuclides for potential use in radioimmunotherapy. Hell J Nucl Med 2007; 10(2): 82-8.
102. Andersson H, Cederkrantz E, Back T, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study. J Nucl Med 2009; 50(7): 1153-60.
103. Jurcic J, Larson S, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100(4): 12339.
104. Mulford D, Scheinberg D, Jurcic J. The promise of targeted {alpha}-particle therapy. J Nucl Med 2005; 46(Suppl 1): 199S-204S.
105. Santoro L, Boutaleb S, Garambois V, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med 2009; 50(12): 2033-41.